Kaleo Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for KALEO INC, and what generic alternatives to KALEO INC drugs are available?
KALEO INC has four approved drugs.
There are forty US patents protecting KALEO INC drugs.
There are one hundred and forty-six patent family members on KALEO INC drugs in fifteen countries and one supplementary protection certificate in one country.
Summary for Kaleo Inc
| International Patents: | 146 |
| US Patents: | 40 |
| Tradenames: | 4 |
| Ingredients: | 2 |
| NDAs: | 4 |
Drugs and US Patents for Kaleo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | BX | RX | Yes | Yes | 8,313,466 | See Plans and Pricing | Y | See Plans and Pricing | ||
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | 8,206,360 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | 9,238,108 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | DISCN | Yes | No | 8,016,788 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | BX | RX | Yes | Yes | 8,926,594 | See Plans and Pricing | Y | See Plans and Pricing | ||
| Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | DISCN | Yes | No | 8,226,610 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Kaleo Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2020501834 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2012118729 | See Plans and Pricing |
| United Kingdom | 2456245 | See Plans and Pricing |
| European Patent Office | 2667926 | See Plans and Pricing |
| Japan | 5680852 | See Plans and Pricing |
| Denmark | 2285360 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Kaleo Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | See Plans and Pricing | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
